The most common adverse events reported in the neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin arm were pruritus, alopecia, diarrhea, fatigue and anemia. No new safety signals were ...

The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient ...

Pembrolizumab plus platinum-based chemotherapy has demonstrated efficacy as first-line treatment for advanced penile cancer in a phase 2 trial. The results were published in JAMA Oncology.

The LITESPARK-022 and LITESPARK-011 trials evaluated combination regimens containing belzutifan in patients with advanced clear cell RCC.

The addition of pembrolizumab (Keytruda) to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) did not improve overall or radiographic progression-free survival versus ...

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Background: Combination therapy with the ...

The impact of induction chemotherapy response to survival outcomes in oropharyngeal cancer. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full ...

So, I think more to come on how first line selection might evolve in the next few years depending on results from other ...

The median overall survival was 19.6 months with pembrolizumab plus docetaxel and 19.0 months with docetaxel alone. The combination of pembrolizumab and docetaxel does not improve outcomes over ...